Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate
Cohort study of 3909 patients suggest continued ACE inhibitor or angiotensin II receptor blocker use is associated with cardiovascular health benefits in individuals with an eGFR below 30 mL/min/1.73m2, without increased risk of progression to end-stage kidney disease.
Source:
JAMA Internal Medicine
SPS commentary:
A total of 35.1% of those who discontinued ACE-I or ARB therapy and 29.4% who did not discontinue therapy died during a median follow-up of 2.9 years.
In a related editorial, the authors note that despite these findings, it is important to assess each patient within their own clinical context.